Form 4: Daxor Corp Director Granted Stock Options Contingent on SEC Plan Approval

Daxor Corp's Director, Caleb DesRosiers, was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Summary

• Caleb DesRosiers, a Director of Daxor Corp (DXR), was granted 2,500 stock options.
• The options have an exercise price of $9.29 per share.
• The grant is contingent upon the Securities & Exchange Commission (SEC) approving an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• The options will vest in three annual installments: 833 options on June 24, 2025; 833 options on June 24, 2026; and 834 options on June 24, 2027.
• The options expire on June 24, 2030.

Sentiment

Score: 6

Explanation: The document reports a standard director compensation event, which is generally positive for aligning interests but carries a minor contingency. It's a neutral to slightly positive event.

Positives

• The grant of stock options aligns the interests of Director Caleb DesRosiers with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director over a three-year period.

Negatives

• The stock option grant, if exercised, could lead to minor dilution for existing shareholders, although the amount is small (2,500 shares).

Risks

• The stock option grant is contingent on the approval of the Securities & Exchange Commission (SEC) to amend the Daxor Corporation 2020 Incentive Compensation Plan, meaning the grant is not yet finalized.

Future Outlook

The future outlook indicates that the stock options granted to Director Caleb DesRosiers are subject to a three-year vesting schedule, with installments on June 24, 2025, June 24, 2026, and June 24, 2027. The grant itself is contingent on future SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Management Comments

• "Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ('SEC') to amend the Daxor Corporation 2020 Incentive Compensation Plan (the 'Plan')."
• "The stock options will vest in three (3) installments June 24, 2025 (833); June 24, 2026 (833); June 24, 2027 (834)."

Industry Context

This filing reflects a common practice in corporate governance where publicly traded companies grant equity-based compensation, such as stock options, to their directors and executives. This is typically done to align the interests of management with shareholders and to incentivize long-term performance and retention. The contingency on SEC approval for plan amendments is also a standard regulatory step for such compensation plans.

Corporate Governance

Related Party Transactions

• The grant of stock options to Caleb DesRosiers, a Director of Daxor Corp, constitutes a related party transaction as it involves compensation from the company to a member of its management.

Stakeholder Impact

• Shareholders: Potential minor dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned for general employees, but the amendment to the 2020 Incentive Compensation Plan could affect future equity grants for other eligible participants.

Next Steps

• Approval by the Securities & Exchange Commission (SEC) of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Vesting of stock options in three installments on June 24, 2025, June 24, 2026, and June 24, 2027.

Key Dates

Keywords

Daxor Corp, DXR, SEC Form 4, Stock Options, Director Compensation, Caleb DesRosiers, Incentive Compensation Plan, Beneficial Ownership, Corporate Governance